WO2015044961A2 - Pharmaceutical composition comprising capecitabine and cyclophosphamide - Google Patents

Pharmaceutical composition comprising capecitabine and cyclophosphamide Download PDF

Info

Publication number
WO2015044961A2
WO2015044961A2 PCT/IN2014/000625 IN2014000625W WO2015044961A2 WO 2015044961 A2 WO2015044961 A2 WO 2015044961A2 IN 2014000625 W IN2014000625 W IN 2014000625W WO 2015044961 A2 WO2015044961 A2 WO 2015044961A2
Authority
WO
WIPO (PCT)
Prior art keywords
capecitabine
cyclophosphamide
layer
pharmaceutical composition
excipients
Prior art date
Application number
PCT/IN2014/000625
Other languages
French (fr)
Other versions
WO2015044961A3 (en
Inventor
Priyank PATEL
Mayur Patel
Mahendra Patel
Balvir SINGH
Ashish Sehgal
Original Assignee
Intas Pharmaceuticals Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intas Pharmaceuticals Limited filed Critical Intas Pharmaceuticals Limited
Priority to EP14850037.4A priority Critical patent/EP3052130B1/en
Priority to MX2016004094A priority patent/MX2016004094A/en
Priority to AU2014326142A priority patent/AU2014326142B2/en
Priority to ES14850037T priority patent/ES2753435T3/en
Priority to US15/025,819 priority patent/US20160243034A1/en
Priority to BR112016007031A priority patent/BR112016007031A8/en
Priority to CA2925960A priority patent/CA2925960A1/en
Publication of WO2015044961A2 publication Critical patent/WO2015044961A2/en
Publication of WO2015044961A3 publication Critical patent/WO2015044961A3/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/675Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/2833Organic macromolecular compounds
    • A61K9/284Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846Poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Definitions

  • This present invention relates to pharmaceutical compositions comprising fixed dose combinations of capecitabine and cyclophospham ide, processes for the preparation thereof, and their use to treat cancer diseases.
  • capecitabine is the most commonly-used agent.
  • Capecitabine has been approved by the Food and Drug Administration in the treatment of Metastatic breast cancer (METASTATIC BREAST CANCER) patients resistant to anthracyc lines and/or taxanes.
  • Capecitabine widely used in different combination regimen due to better therapeutic & safety profile with lower side effects.
  • the combination partner of capecitabine play important role for the activation of thym idine phosphorylase (TP) enzyme, which convert the capecitabine to active 5-FU.
  • TP thym idine phosphorylase
  • Cyclophosphamide is an anti-cancer chemotherapy drug. This medication is classified as an alkylating agent. Cyclophosphamide is a prodrug, converted in the liver to active forms that have slow down the growth of cancer cells. Cyclophosphamide requires enzymatic and chem ical activation to produces active form. Cyclophospham ide is used alone or in combination with other drugs to treat various cancers like METASTATIC BREAST CANCER, ovarian cancer, leukemia. When given by orally, cyclophosphamide shows superior efficacy than when it is given intravenously.
  • Inventors of the present invention investigated the development of pharmaceutical composition for oral administration.
  • a stable pharmaceutical composition was not obtained due to incompatibi lity between the two therapeutic agents, specifically total impurity levels were found to be increased drastically.
  • the inventors have provided herewith a novel stable pharmaceutical composition which can be formulated for oral administration. Furthermore the present invention provide the advantages of combination therapy while reducing the number of prescriptions, number of tablets to be taken which results in better patient compliance and attendant administrative costs. Combination therapies with agents having complementary mechanisms of action may provide advantages of each type of agent and reduce some of the adverse effects of high-dose of individual drugs.
  • the object of the present invention is to provide a pharmaceutical composition comprising fixed dose combination of capecitabine and cyclophosphamide.
  • Another object of the present invention is to provide a pharmaceutical composition comprising fixed dose combination of capecitabine and cyclophosphamide in a solid dosage form for oral administration.
  • Another object of the present invention is to provide a pharmaceutical composition comprising fixed dose combination in the form of bilayer tablet.
  • Another object of the present invention to provide a pharmaceutical composition
  • a pharmaceutical composition comprising a first layer & second layer, wherein the first layer comprises capecitabine and one or more excipients, and the second layer comprises cyclophosphamide and one or more excipients.
  • Another object of the present invention to provide a bilayer tablet comprising a first layer & second layer, wherein the first layer comprises capecitabine and one or more excipients, optionally a film coating that covers both layer.
  • the first layer comprises capecitabine and one or more excipients
  • the second layer comprises cyclophosphamide and one or more excipients.
  • the present invention relates to pharmaceutical compositions comprising fixed dose combinations of capecitabine and cyclophospham ide preferably in sol id dosage form for oral administration, processes for the preparation thereof, and their use to treat cancer diseases. Further the combination of capecitabine and cyclophosphamide is an effective, convenient and well-tolerated regimen for Metastatic Breast Cancer.
  • the present invention relates to a fixed dose combination comprising capecitabine and cyclophosphamide in the form of bilayer tablet.
  • Oral combination of capecitabine and cyclophosphamide are conventional drugs for the treatment and are an effective and we 11 -tolerated regimen for Metastatic Breast Cancer.
  • the pharmaceutical composition comprising fixed dose combination present in solid dosage form, particularly in oral form.
  • the sol id dosage can be bi layer tablet, multi layer tablet, film-coated tablet, preferably bi layer tablet.
  • a fixed dose combination according to present invention provide a pharmaceutically bi layer tablet composition comprising a first layer & second layer, wherein the first layer comprises capecitabine and one or more excipients, and the second layer comprises cyclophosphamide and one or more excipients.
  • the present invention to provide a bilayer tablet comprising a first layer & second layer, wherein- the first layer comprises capecitabine and one or more excipients, and optionally a film coating that covers both layer.
  • excipients which may be used may typically be selected from the group consisting of one or more diluents or fillers, one or more binders, one or more gl idants, one or more disintegrants, one or more lubricants, and the like.
  • the amount of each excipient in a solid dosage formulation may vary within ranges conventional in the art.
  • the pharmaceutical composition described herein may be prepared by conventional technology well known to those ski lled in the art such as wet granulation, dry granulation and direct compression and the l ike.
  • the first layer comprising capecitabine can be prepared by wet granulation as hereinafter described whilst the second layer comprising cyclophospham ide can be prepared by blending the excipients for direct compression.
  • second layer comprising cyclophosphamide can be prepared by wet granulation. Both the layers can then be combined and compressed together as herein after described.
  • the bi layer tablet dosage form may comprise a fi lm coating. Suitable fi lm coating is known and commercial ly available or can be made according to known methods.
  • the film coating material is a polymeric film coating material comprising hydroxypropylmethyl cellulose, polyethylene glycol, polysorbate, sodium carboxy methyl cel l ulose, Talc. Titanium dioxide, simethicon, Eudragit, purified water and colorant.
  • a bilayer tablet according to present invention generally contains 50-1800 mg, preferably 100-1500 mg, more preferably 300-800 mg capecitabine; and 1 0- 1 00 mg, preferably 20-80 mg, more preferably 20-60mg cyclophosphamide.
  • Presently preferred forms are bilayer tablet comprising 300/20 mg, 400/20 mg, 600/40 and 700/30 mg of capecitabine and cyclophosphamide respectively.
  • the first tablet layer according to present invention comprises capecitabine as active agent and one or more excipients.
  • Capecitabine containing first layer of the invention is prepared by wet granulation.
  • Alternative method for granulation of the active ingredient and excipients with a granulation liquid are fluid bed granulation or top spray granulation.
  • the granulating l iquid is a solvent such as purified water, ethanol, isopropanol, acetone or mixture thereof, preferably purified water.
  • the solvent is a volatile component, which does not remain in the final product.
  • Excipients of the first layer may be particularly selected from the group consisting of one or more fi l lers, one or more binders, one or more disintegrants, and one or more lubricants.
  • a bilayer tablet comprising first layer is prepared by wet granulation comprising following steps:
  • capecitabine a) sifting of capecitabine, one or more filler, one or more disintegrant through appropriate mesh and m ixing in a suitable m ixer,
  • step (b) carrying out fluid bed granulation using the granulating liquid of step (b) for spraying onto the mixture of step (a),
  • step (c) after completion of the granulation drying and optionally screening the granulate obtained in step (c),
  • step (d) optionally blending the granulate obtained in step (d) with additional excipients;
  • step (e) lubricating the blended granules obtained in step (e) to prepare the final composition of first layer.
  • binder can be added with the blend obtained in step (a) & further granulation is done with suitable solvent which would act as a granulation liquid.
  • filler for first layer examples include, without being limited to microcrystalline cellulose, mannitol, sucrose or other sugar or sugar derivatives, low substituted HPC, dicalcium phosphate, lactose and combination thereof.
  • binder for first layer examples include, without being limited to polyvinylpyrrolidone, hydroxypropyl methylcellulose, hydroxypropyl cellulose, pregelatinized starch, maize starch, microcrystalline cellulose (e.g., cellulose MK GR), and combinations thereof.
  • disintegrant for first layer examples include, without being limited to croscarmelose sodium, crospovidone, sodium starch glycolate, starch, pregelatinized starch and combination thereof
  • lubricant for first layer examples include, without being limited to magnesium stearate, calcium stearate, aluminum or calcium silicate, stearic acid, talc and combinations thereof.
  • the second tablet layer accord ing to present invention comprises cyclophospham ide as active agent and one or more excipients.
  • the second layer comprising cyclophosphamide having D90 particle size less than 300 microns, more preferably 100 microns.
  • bilayer tablet comprising second layer is prepared by direct compression comprising following steps:
  • step (b) adding one or more lubricant in mixture obtained in step (a) and blending them until obtaining a homogenous powder mixture;
  • bilayer tablet comprising second layer can also be prepared by wet granulation comprising following steps: (a) Co-sift one or more pharmaceutically acceptable excipients and prepare a mixture,
  • step (e) Blend the granules obtained in step (c) and drug mixture of step (d),
  • step (f) Lubricate the blended mixture obtained in step (e) to form final blend for second layer.
  • Excipients of the second layer may be particularly selected from the group consisting of one or more fillers, one or more binders, one or more disintegrants, and one or more lubricants.
  • fi ller for second layer examples include, without being limited to dibasic calcium phosphate anhydrous, microcrystalline cellulose, lactose, mannitol, sucrose or other sugar or sugar derivatives, low substituted HPC, pregelatinized starch, and combination thereof.
  • binder for second layer examples include, without being lim ited to polyvinylpyrrolidone, povidone, copovidone, hydroxypropyl lmethylcellulose, hydroxypropyl cellulose, pregelatinized starch, maize starch, microcrystalline cellulose (e.g., cellulose MK GR), and combinations thereof.
  • disintegrant for second layer examples include, without being l im ited to croscarmelose sodium, crospovidone, sodium starch glycolate, starch, pregelatinized starch and combination thereof.
  • lubricant for second layer examples include, without being limited to magnesium stearate, calcium stearate, aluminum or calcium silicate, stearic acid, talc and combinations thereof.
  • the first & second tablet layer prepared as described hereinabove may be compressed in the usual manner in a bilayer tablet press.
  • Another preferred aspect of the present invention also includes an optional fi lm coating on the bilayer tablet.
  • the details regarding the film coating material, component are as described herein above.
  • capecitabine & cyclophosphamide are physically incompatible substances.
  • both the drugs were kept on 40°C (open) for 1 month, different type of impurities related with cyclophosphamide are obtained during preformulation studies.
  • the % impurities related with cyclophosphamide are obtained during the preformulation studies are as below.
  • Impurity A of cyclophosphamide is chemically 3-[3-(2-chloroethylamino) ethyl amino] propyl dihydrogen phosphate.
  • Impurity B of cyclophosphamide is 3-aminopropyl dihydrogen phosphate.
  • Impurity C of cyclophosphamide is 3-3 chloroethyl-2-oxo-2-hydroxy- 1 , 3, 6. 2 oxadiazaphosphonane.
  • Acceptable lim its of the above said impurities of cyclophosphamide according to the present invention are individually not more than 0.5% w/w and the total impurity of cyclophosphamide should not be more than 3% w/w, when determined after one month when kept at 40°C.
  • the present invention provides a pharmaceutical composition comprising fixed dose combination of capecitabine and cyclophosphamide thereof have a greater potential for treatment of metastatic breast cancer.
  • the present invention provides a better therapeutic efficacy by combined administered of capecitabine and cyclophosphamide rather than when used separately.
  • step 2 Place materials of step 1 in fluid bed energizer and dry mix for 5 min at 50°C.
  • Bilayer tablets were compressed using blend of step 8 and blend of step 10 using rotary tablet compression machine.
  • Tablets were coated using coating solution containing polyethylene glycol 6000, polysorbate 80, sodiumcarboxymethyl cellulose, talc, titanium dioxide, eudragit NE30D, ferric oxide red, ferric oxide yellow and purified water.
  • step 10 Dry mix and granulate the blend of step 9 using Purified water. Dry the granules at 60°C. Mill the granules through co mill.
  • Process for preparation of film coating is similar as example 1 and 2.
  • the bilayer tablet of fixed dose combination of capecitabine and cyclophosphamide prepared as per the composition of Example 1 to example 4 were subjected to dissolution studies in 900 ml of phosphate buffer pH 6.8 at 37 ⁇ 0.5°C using basket apparatus with rotational speed at 100 rpm.
  • Table 2 provides dissolution profile of tablets prepared according example 1 to example 4.
  • Impurity profile of the pharmaceutical compositions according to examples 1 to 4 meets the acceptance criteria of individual and total impurities of cyclophosphamide as disclosed hereinabove.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

This present invention relates to pharmaceutical compositions comprising fixed dose combinations of capecitabine and cyclophosphamide, processes for the preparation thereof, and their use to treat cancer diseases.

Description

PHARMACEUTICAL COMPOSITION COMPRISING CAPECITABINE
AND CYCLOPHOSPHAMIDE
FIELD OF THE INVENTION
This present invention relates to pharmaceutical compositions comprising fixed dose combinations of capecitabine and cyclophospham ide, processes for the preparation thereof, and their use to treat cancer diseases.
BACKGROUND OF THE INVENTION
Among potential active cytotoxic drugs, capecitabine is the most commonly-used agent. Capecitabine has been approved by the Food and Drug Administration in the treatment of Metastatic breast cancer (METASTATIC BREAST CANCER) patients resistant to anthracyc lines and/or taxanes. Capecitabine widely used in different combination regimen due to better therapeutic & safety profile with lower side effects. In addition, the combination partner of capecitabine play important role for the activation of thym idine phosphorylase (TP) enzyme, which convert the capecitabine to active 5-FU.
Cyclophosphamide is an anti-cancer chemotherapy drug. This medication is classified as an alkylating agent. Cyclophosphamide is a prodrug, converted in the liver to active forms that have slow down the growth of cancer cells. Cyclophosphamide requires enzymatic and chem ical activation to produces active form. Cyclophospham ide is used alone or in combination with other drugs to treat various cancers like METASTATIC BREAST CANCER, ovarian cancer, leukemia. When given by orally, cyclophosphamide shows superior efficacy than when it is given intravenously.
Further interest in oral ' agents for the treatment of METASTATIC BREAST CANCER has increased because many patients prefer oral to intravenous regimens due to administered at home, no need to hospitalization, fear of needles, and lower associated costs. The combination of capecitabine and cyclophosphamide in present invention potential ly provides an attractive, all oral alternative, giving patients more freedom and a sense of control over their treatment. With increasing experience of capecitabine after its introduction, many clinicians found that oral administration of cyclophosphamide and capecitabine may have a greater potential for treatment of METASTATIC BREAST CANCER due to anti- angiogenesis resulting from the metronomic dosage and upregulation of thymidine phosphorylase by capecitabine. In particular, a marked reduction in the tumor volume was seen during the time period coincident with the dThdPase up-regulation. In addition several clinical studies show that the efficacy of cyclophosphamide in combination with capecitabine was more than just additive to synergistic effects.
In view of above, there is still an existing and continual need for a fixed dose oral combination comprising capecitabine and cyclophosphamide. The inventors of the present invention address the need to provide a fixed dose combination of capecitabine and cyclophosphamide to allow convenient administration of both the drugs as a single tablet and to effective treatment with good acceptability at lower dose.
Inventors of the present invention investigated the development of pharmaceutical composition for oral administration. However, a stable pharmaceutical composition was not obtained due to incompatibi lity between the two therapeutic agents, specifically total impurity levels were found to be increased drastically.
To overcome the issue related to incompatibilities of both therapeutic agents & pharmaceutical excipients, the inventors have provided herewith a novel stable pharmaceutical composition which can be formulated for oral administration. Furthermore the present invention provide the advantages of combination therapy while reducing the number of prescriptions, number of tablets to be taken which results in better patient compliance and attendant administrative costs. Combination therapies with agents having complementary mechanisms of action may provide advantages of each type of agent and reduce some of the adverse effects of high-dose of individual drugs.
OBJECTS OF THE INVENTION
The object of the present invention is to provide a pharmaceutical composition comprising fixed dose combination of capecitabine and cyclophosphamide.
Another object of the present invention is to provide a pharmaceutical composition comprising fixed dose combination of capecitabine and cyclophosphamide in a solid dosage form for oral administration.
Another object of the present invention is to provide a pharmaceutical composition comprising fixed dose combination in the form of bilayer tablet.
Another object of the present invention to provide a pharmaceutical composition comprising a first layer & second layer, wherein the first layer comprises capecitabine and one or more excipients, and the second layer comprises cyclophosphamide and one or more excipients.
Another object of the present invention to provide a bilayer tablet comprising a first layer & second layer, wherein the first layer comprises capecitabine and one or more excipients, optionally a film coating that covers both layer. In yet another object of the invention is to provide a process for the preparation of pharmaceutical composition comprising a first layer & second layer, wherein the first layer comprises capecitabine and one or more excipients, and the second layer comprises cyclophosphamide and one or more excipients.
_
SUMMARY OF THE INVENTION
The present invention relates to pharmaceutical compositions comprising fixed dose combinations of capecitabine and cyclophospham ide preferably in sol id dosage form for oral administration, processes for the preparation thereof, and their use to treat cancer diseases. Further the combination of capecitabine and cyclophosphamide is an effective, convenient and well-tolerated regimen for Metastatic Breast Cancer.
DETAILED DESCRIPTION
Unless otherwise indicated, terms in this specification are intended to have their ordinary meaning in the relevant art.
The present invention relates to a fixed dose combination comprising capecitabine and cyclophosphamide in the form of bilayer tablet. Oral combination of capecitabine and cyclophosphamide are conventional drugs for the treatment and are an effective and we 11 -tolerated regimen for Metastatic Breast Cancer.
According to present invention the pharmaceutical composition comprising fixed dose combination present in solid dosage form, particularly in oral form. The sol id dosage can be bi layer tablet, multi layer tablet, film-coated tablet, preferably bi layer tablet. According to one of the embodiments, a fixed dose combination according to present invention provide a pharmaceutically bi layer tablet composition comprising a first layer & second layer, wherein the first layer comprises capecitabine and one or more excipients, and the second layer comprises cyclophosphamide and one or more excipients.
Preferably, the present invention to provide a bilayer tablet comprising a first layer & second layer, wherein- the first layer comprises capecitabine and one or more excipients, and optionally a film coating that covers both layer.
In general, excipients which may be used may typically be selected from the group consisting of one or more diluents or fillers, one or more binders, one or more gl idants, one or more disintegrants, one or more lubricants, and the like. The amount of each excipient in a solid dosage formulation may vary within ranges conventional in the art.
The pharmaceutical composition described herein may be prepared by conventional technology well known to those ski lled in the art such as wet granulation, dry granulation and direct compression and the l ike.
More preferably in the present invention, the first layer comprising capecitabine can be prepared by wet granulation as hereinafter described whilst the second layer comprising cyclophospham ide can be prepared by blending the excipients for direct compression.
Alternatively second layer comprising cyclophosphamide can be prepared by wet granulation. Both the layers can then be combined and compressed together as herein after described. Furthermore, the bi layer tablet dosage form may comprise a fi lm coating. Suitable fi lm coating is known and commercial ly available or can be made according to known methods.
According to present invention the film coating material is a polymeric film coating material comprising hydroxypropylmethyl cellulose, polyethylene glycol, polysorbate, sodium carboxy methyl cel l ulose, Talc. Titanium dioxide, simethicon, Eudragit, purified water and colorant.
According to one of the embodiments, a bilayer tablet according to present invention generally contains 50-1800 mg, preferably 100-1500 mg, more preferably 300-800 mg capecitabine; and 1 0- 1 00 mg, preferably 20-80 mg, more preferably 20-60mg cyclophosphamide. Presently preferred forms are bilayer tablet comprising 300/20 mg, 400/20 mg, 600/40 and 700/30 mg of capecitabine and cyclophosphamide respectively.
According to one of the embodiments, the first tablet layer according to present invention comprises capecitabine as active agent and one or more excipients. Capecitabine containing first layer of the invention is prepared by wet granulation. Alternative method for granulation of the active ingredient and excipients with a granulation liquid are fluid bed granulation or top spray granulation.
In the wet granulation process the granulating l iquid is a solvent such as purified water, ethanol, isopropanol, acetone or mixture thereof, preferably purified water. The solvent is a volatile component, which does not remain in the final product.
Excipients of the first layer may be particularly selected from the group consisting of one or more fi l lers, one or more binders, one or more disintegrants, and one or more lubricants. According to present invention a bilayer tablet comprising first layer is prepared by wet granulation comprising following steps:
a) sifting of capecitabine, one or more filler, one or more disintegrant through appropriate mesh and m ixing in a suitable m ixer,
b) dissolving a binder in a solvent to produce a granu lation liquid,
c) carrying out fluid bed granulation using the granulating liquid of step (b) for spraying onto the mixture of step (a),
d) after completion of the granulation drying and optionally screening the granulate obtained in step (c),
e) optional ly blending the granulate obtained in step (d) with additional excipients; and
f) lubricating the blended granules obtained in step (e) to prepare the final composition of first layer.
Alternatively, binder can be added with the blend obtained in step (a) & further granulation is done with suitable solvent which would act as a granulation liquid.
Examples of filler for first layer include, without being limited to microcrystalline cellulose, mannitol, sucrose or other sugar or sugar derivatives, low substituted HPC, dicalcium phosphate, lactose and combination thereof.
Examples of binder for first layer include, without being limited to polyvinylpyrrolidone, hydroxypropyl methylcellulose, hydroxypropyl cellulose, pregelatinized starch, maize starch, microcrystalline cellulose (e.g., cellulose MK GR), and combinations thereof. Examples of disintegrant for first layer include, without being limited to croscarmelose sodium, crospovidone, sodium starch glycolate, starch, pregelatinized starch and combination thereof
Examples of lubricant for first layer include, without being limited to magnesium stearate, calcium stearate, aluminum or calcium silicate, stearic acid, talc and combinations thereof.
The second tablet layer accord ing to present invention comprises cyclophospham ide as active agent and one or more excipients.
According to one of the embodiments, the second layer comprising cyclophosphamide having D90 particle size less than 300 microns, more preferably 100 microns.
According to present invention bilayer tablet comprising second layer is prepared by direct compression comprising following steps:
a) mixing the cyclophosphamide with one or more filler, one or more binder, one or more disintegrant in a suitable mixer
b) adding one or more lubricant in mixture obtained in step (a) and blending them until obtaining a homogenous powder mixture; and
c) compressing the final powder mixture to form final composition of second layer.
According to present invention bilayer tablet comprising second layer can also be prepared by wet granulation comprising following steps: (a) Co-sift one or more pharmaceutically acceptable excipients and prepare a mixture,
(b) granulate the above mixture by using solvent,
(c) dry the above granulate and mi l l ing the dried granu les,
(d) prepare the drug mixture separately by co-sift cyclophosphamide and one or more pharmaceutically acceptable excipients.
(e) Blend the granules obtained in step (c) and drug mixture of step (d),
(f) Lubricate the blended mixture obtained in step (e) to form final blend for second layer.
Excipients of the second layer may be particularly selected from the group consisting of one or more fillers, one or more binders, one or more disintegrants, and one or more lubricants.
Examples of fi ller for second layer include, without being limited to dibasic calcium phosphate anhydrous, microcrystalline cellulose, lactose, mannitol, sucrose or other sugar or sugar derivatives, low substituted HPC, pregelatinized starch, and combination thereof.
Examples of binder for second layer include, without being lim ited to polyvinylpyrrolidone, povidone, copovidone, hydroxypropyl lmethylcellulose, hydroxypropyl cellulose, pregelatinized starch, maize starch, microcrystalline cellulose (e.g., cellulose MK GR), and combinations thereof.
Examples of disintegrant for second layer include, without being l im ited to croscarmelose sodium, crospovidone, sodium starch glycolate, starch, pregelatinized starch and combination thereof. Examples of lubricant for second layer include, without being limited to magnesium stearate, calcium stearate, aluminum or calcium silicate, stearic acid, talc and combinations thereof. For preparing a bilayer tablet according to present invention, the first & second tablet layer prepared as described hereinabove may be compressed in the usual manner in a bilayer tablet press.
Another preferred aspect of the present invention also includes an optional fi lm coating on the bilayer tablet. The details regarding the film coating material, component are as described herein above.
According to present invention capecitabine & cyclophosphamide are physically incompatible substances. When both the drugs were kept on 40°C (open) for 1 month, different type of impurities related with cyclophosphamide are obtained during preformulation studies. The % impurities related with cyclophosphamide are obtained during the preformulation studies are as below.
Table 1 : Pre-formulation studies related to combination of Capecitabine + cyclophospham ide
Figure imgf000011_0001
[Capecitabine + Initial ND ND ND 0.575% 1.010% Cyclophosphamide]
+ Croscarmellose 1 moqth ND ND 0.086% 5.014% 5.893% Sodium
[Capecitabine + Initial ND ND ND 0.022% 0. 192% Cyclophosphamide]
+ Magnesium 1 month ND ND 0.091 % 6.658% 8.220% Stearate
•Impurity A of cyclophosphamide is chemically 3-[3-(2-chloroethylamino) ethyl amino] propyl dihydrogen phosphate. •Impurity B of cyclophosphamide is 3-aminopropyl dihydrogen phosphate.
•Impurity C of cyclophosphamide is 3-3 chloroethyl-2-oxo-2-hydroxy- 1 , 3, 6. 2 oxadiazaphosphonane.
•Impurity D of cyclophospha ide is Bis (2-chloroethyI)amine hydrochloride.
Acceptable lim its of the above said impurities of cyclophosphamide according to the present invention are individually not more than 0.5% w/w and the total impurity of cyclophosphamide should not be more than 3% w/w, when determined after one month when kept at 40°C.
Accordingly, the pre-formulation studies for combination of capecitabine and cyclophospham ide does not comply with the above said acceptable l imits
Further the present invention provides a pharmaceutical composition comprising fixed dose combination of capecitabine and cyclophosphamide thereof have a greater potential for treatment of metastatic breast cancer.
In addition, the present invention provides a better therapeutic efficacy by combined administered of capecitabine and cyclophosphamide rather than when used separately.
EXAMPLES
The present invention has been described by way of example only. It is to be recognized that modifications falling within the scope and spirit of the claims, which would be obvious to a person skilled in the art based upon the disclosure herein, are
I 1 also considered to be included within the scope of this invention. The scope of the invention is in no manner limited by the disclosed example.
Example 1 and 2
Figure imgf000013_0001
Brief Manufacturing process of Example 1 and 2 Preparation of Capecitabine Layer:
1 . Sift capecitabine, microcrystal line cellulose (Avicel PH I 1 2), croscarmel lose sodium, through ASTM 20# sieve.
2. Place materials of step 1 in fluid bed energizer and dry mix for 5 min at 50°C.
3. Dissolve hypromel iose E5 in Purified Water using stirrer.
4. Granulate materials in fluid bed energizer usi ng binder solution of step 3.
5. Dry the granules in fluid bed energizer at 55°C.
6. Pass the dried granules through ASTM 20# sieve.
7. Sift croscarmellose sodium through ASTM 20# sieve and mix with granules of step 6 in blender for 10 mins at 25 RPM.
8. Sift magnesium stearate through ASTM 40# sieve and mix with blend of step 7 for 3 mins.
Preparation of Cyclophosphamide Layer:
9. Separately, sift cyclophosphamide, microcrystalline cellulose (Avicel PH 1 12), povidone k-90 and croscarmellose sodium, through ASTM 20# sieve. Mix it in blender for 10 m ins at 25 RPM.
1 0. Sift magnesium stearate through 40# sieve and mix with blend of step 9 for 3 mins at 25 RPM.
Compression of Bilayer tablet
1 1. Bilayer tablets were compressed using blend of step 8 and blend of step 10 using rotary tablet compression machine.
1 2. Tablets were coated using coating solution containing polyethylene glycol 6000, polysorbate 80, sodiumcarboxymethyl cellulose, talc, titanium dioxide, eudragit NE30D, ferric oxide red, ferric oxide yellow and purified water.
13. Pack the film coated tablets in suitable pack using packaging machine. Example 3 and 4
Figure imgf000015_0001
Brief Man ufactu ring process of Example 3 and 4 Preparation of Capecitabine Layer:
Process for the preparation of capecitabine layer was similar as per example 1 and 2.
Preparation of Cyclophosphamide Layer: 9. Co-sift microcrystal line cel lu lose, Dibasic calcium phosphate dehydrate,
Pregelatinized starch and Povidone K-90 through 30#ASTM sieve.
10. Dry mix and granulate the blend of step 9 using Purified water. Dry the granules at 60°C. Mill the granules through co mill.
1 1 . Separately, co-sift cyclophosphamide, pregelatinized starch (Starch 1 500) and croscarmel lose sodium through 40# ASTM sieve.
12. Co-sift talc and colloidal anhydrous silica-E through 40#ASTM sieve. Ferric oxide yellow was sifted through 80# ASTM sieve.
13. Blend the granules of step 10, 1 1 and 12 in blender.
14. Sift magnesium stearate through 40# sieve and mix with blend of step 13.
Compression & Film coating of Bilayer tablet
Process for preparation of film coating is similar as example 1 and 2.
In-vitro dissolution profile
The bilayer tablet of fixed dose combination of capecitabine and cyclophosphamide prepared as per the composition of Example 1 to example 4 were subjected to dissolution studies in 900 ml of phosphate buffer pH 6.8 at 37±0.5°C using basket apparatus with rotational speed at 100 rpm. Table 2 provides dissolution profile of tablets prepared according example 1 to example 4.
Figure imgf000017_0001
The above dissolution study data comply with the dissolution testing requirements of immediate release solid oral dosage forms.
Stability study
The study of cyclophospham ide impurities A, B, C, and D profile of example 1 to 4 were carried out at 30°C / 65% RH for 1 month. The impurity profile results obtained are as below:
Figure imgf000017_0002
Impurity profile of the pharmaceutical compositions according to examples 1 to 4 meets the acceptance criteria of individual and total impurities of cyclophosphamide as disclosed hereinabove.

Claims

We claim :
1. A solid oral pharmaceutical composition comprising a fixed dose combination of capecitabine and cyclophosphamide and one or more pharmaceutically acceptable excipients thereof.
2. The sol id oral pharmaceutical according to claim I comprising a first layer and second layer wherein the first layer comprises capecitabine and one or more pharmaceutically excipients and the second layer comprises cyclophosphamide and one or more pharmaceutically acceptable excipients and further optionally comprising film coating that covers both the layers.
3. The sol id oral pharmaceutical composition according to any preceding claim, wherein the first layer contains 100 to 1500 mg of capecitabine
4. The solid oral pharmaceutical composition according to any preceding claim, wherein the second later contains 10-100 mg of cyclophosphamide.
5. The solid oral pharmaceutical composition according to any preceding claim, wherein the pharmaceutical ly acceptable excipients can be selected from one or more di luents or fillers, one or more binders, one or more glidants, one or more disintegrants, one or more glidants, one or more lubricants and combinations thereof.
6. A process for the preparation of pharmaceutical composition comprising a first layer and second layer wherein the first layer comprises capecitabine and one or more pharmaceutical ly excipients and the second layer comprises cyclophosphamide and one or more pharmaceutically acceptable excipients and further optionally comprising film coating that covers both the layers..
7. A solid oral bilayer pharmaceutical composition comprising a fixed dose combination of capecitabine and cyclophosphamide for use in the preparation of medicament for the treatment of metastatic breast cancer.
8. A method of using the pharmaceutical composition of claim 1 for treating the metastatic breast cancer.
PCT/IN2014/000625 2013-09-30 2014-09-29 Pharmaceutical composition comprising capecitabine and cyclophosphamide WO2015044961A2 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
EP14850037.4A EP3052130B1 (en) 2013-09-30 2014-09-29 Pharmaceutical composition comprising capecitabine and cyclophosphamide
MX2016004094A MX2016004094A (en) 2013-09-30 2014-09-29 Pharmaceutical composition comprising capecitabine and cyclophosphamide.
AU2014326142A AU2014326142B2 (en) 2013-09-30 2014-09-29 Pharmaceutical composition comprising capecitabine and cyclophosphamide
ES14850037T ES2753435T3 (en) 2013-09-30 2014-09-29 Pharmaceutical composition comprising Capecitabine and Cyclophosphamide
US15/025,819 US20160243034A1 (en) 2013-09-30 2014-09-29 Pharmaceutical composition comprising capecitabine and cyclophosphamide
BR112016007031A BR112016007031A8 (en) 2013-09-30 2014-09-29 solid oral pharmaceutical composition, process for preparing the solid oral pharmaceutical composition, and use of a solid oral pharmaceutical composition
CA2925960A CA2925960A1 (en) 2013-09-30 2014-09-29 Pharmaceutical composition comprising capecitabine and cyclophosphamide

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN3118/MUM/2013 2013-09-30
IN3118MU2013 IN2013MU03118A (en) 2013-09-30 2014-09-29

Publications (2)

Publication Number Publication Date
WO2015044961A2 true WO2015044961A2 (en) 2015-04-02
WO2015044961A3 WO2015044961A3 (en) 2015-06-04

Family

ID=52744637

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2014/000625 WO2015044961A2 (en) 2013-09-30 2014-09-29 Pharmaceutical composition comprising capecitabine and cyclophosphamide

Country Status (9)

Country Link
US (1) US20160243034A1 (en)
EP (1) EP3052130B1 (en)
AU (1) AU2014326142B2 (en)
BR (1) BR112016007031A8 (en)
CA (1) CA2925960A1 (en)
ES (1) ES2753435T3 (en)
IN (1) IN2013MU03118A (en)
MX (1) MX2016004094A (en)
WO (1) WO2015044961A2 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015189807A1 (en) * 2014-06-12 2015-12-17 Sanofi-Synthelabo (India) Limited Bi-layer tablet formulations of cyclophosphamide and capecitabine and highly fractionated metronomic administration thereof
WO2016046797A1 (en) * 2014-09-26 2016-03-31 Intas Pharmaceuticals Ltd. Pharmaceutical composition having improved content uniformity
WO2017191553A1 (en) * 2016-05-03 2017-11-09 Intas Pharmaceuticals Ltd. Tablet-in-tablet pharmaceutical composition comprising cyclophosphamide and capecitabine

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013028186A1 (en) 2011-08-24 2013-02-28 Oxford Oncology Inc. Low-dose combination chemotherapy

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5047246A (en) * 1988-09-09 1991-09-10 Bristol-Myers Company Direct compression cyclophosphamide tablet
WO2007143212A1 (en) * 2006-06-02 2007-12-13 Ariad Gene Therapeutics, Inc. Capecitabine combination therapy
WO2010134025A2 (en) * 2009-05-20 2010-11-25 Ranbaxy Laboratories Limited Oral compositions of celecoxib
CN103251569B (en) * 2013-05-30 2015-10-28 成都苑东药业有限公司 Capecitabine tablet composition and preparation method thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013028186A1 (en) 2011-08-24 2013-02-28 Oxford Oncology Inc. Low-dose combination chemotherapy

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015189807A1 (en) * 2014-06-12 2015-12-17 Sanofi-Synthelabo (India) Limited Bi-layer tablet formulations of cyclophosphamide and capecitabine and highly fractionated metronomic administration thereof
WO2016046797A1 (en) * 2014-09-26 2016-03-31 Intas Pharmaceuticals Ltd. Pharmaceutical composition having improved content uniformity
US10016447B2 (en) 2014-09-26 2018-07-10 Intas Pharmaceuticals Ltd. Pharmaceutical composition having improved content uniformity
WO2017191553A1 (en) * 2016-05-03 2017-11-09 Intas Pharmaceuticals Ltd. Tablet-in-tablet pharmaceutical composition comprising cyclophosphamide and capecitabine
CN109195609A (en) * 2016-05-03 2019-01-11 印塔斯制药有限公司 Tablet packet troche medical composition comprising cyclophosphamide and capecitabine
US20190142755A1 (en) * 2016-05-03 2019-05-16 Intas Pharmaceuticals Ltd. Tablet-in-tablet pharmaceutical composition comprising cyclophosphamide and capecitabine
EP3452054A4 (en) * 2016-05-03 2019-12-25 Intas Pharmaceuticals Limited Tablet-in-tablet pharmaceutical composition comprising cyclophosphamide and capecitabine

Also Published As

Publication number Publication date
AU2014326142B2 (en) 2019-07-25
US20160243034A1 (en) 2016-08-25
EP3052130A4 (en) 2017-05-31
ES2753435T3 (en) 2020-04-08
BR112016007031A8 (en) 2020-02-27
WO2015044961A3 (en) 2015-06-04
EP3052130B1 (en) 2019-08-07
CA2925960A1 (en) 2015-04-02
AU2014326142A1 (en) 2016-04-21
BR112016007031A2 (en) 2017-08-01
EP3052130A2 (en) 2016-08-10
MX2016004094A (en) 2016-10-28
IN2013MU03118A (en) 2015-08-14

Similar Documents

Publication Publication Date Title
JP5159303B2 (en) Controlled release composition
EP2974720B1 (en) Mosapride sustained-release preparation for providing pharmacological clinical effects with once-a-day administration
JP5442459B2 (en) Salt of 8-[{1- (3,5-bis- (trifluoromethyl) phenyl) -ethoxy} -methyl] -8-phenyl-1,7-diaza-spiro [4.5] decan-2-one Tablet formulations containing and tablets made therefrom
AU2018202635A1 (en) Therapeutic compositions comprising rilpivirine HCl and tenofovir disoproxil fumarate
TWI686215B (en) Oral formulations of deferasirox
MXPA04010496A (en) High drug load tablet.
PL200957B1 (en) Celecoxib compositions and the use thereof
CN110062628B (en) Ruicapalb oral sustained and controlled release pharmaceutical composition and application thereof
KR20200118507A (en) Dosage form compositions comprising an inhibitor of bruton's tyrosine kinase
JP2023065568A (en) Compositions and methods for treating abnormal cell growth
JPH09500910A (en) Film-coated tablets of paracetamol and domperidone
EP3052130B1 (en) Pharmaceutical composition comprising capecitabine and cyclophosphamide
US10016447B2 (en) Pharmaceutical composition having improved content uniformity
WO2018095403A1 (en) Pyridone derivative pharmaceutical composition and preparation method thereof
TWI720115B (en) Preparation method of a pharmaceutical composition comprising quinoline derivatives or salt thereof
JP5365949B2 (en) Orally disintegrating tablets containing low-dose ramosetron
CN109195609A (en) Tablet packet troche medical composition comprising cyclophosphamide and capecitabine
JP6112765B2 (en) Solid preparation containing loxoprofen sodium and dl-methylephedrine hydrochloride
US20210346303A1 (en) Coating method
TW201609197A (en) Mosapride sustained-release formulation providing pharmacological and clinical effects with once-daily administration
US20140322320A1 (en) Novel compositions for emesis control in cancer patients undergoing chemotherapy and methods thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14850037

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 15025819

Country of ref document: US

ENP Entry into the national phase

Ref document number: 2925960

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: MX/A/2016/004094

Country of ref document: MX

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112016007031

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 2014326142

Country of ref document: AU

Date of ref document: 20140929

Kind code of ref document: A

REEP Request for entry into the european phase

Ref document number: 2014850037

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2014850037

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 112016007031

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20160330